FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1994320162> ?p ?o ?g. }

• W1994320162 endingPage "854" @default.
• W1994320162 startingPage "843" @default.
• W1994320162 abstract "Having demonstrated short-term weight loss with liraglutide in this group of obese adults, we now evaluate safety/tolerability (primary outcome) and long-term efficacy for sustaining weight loss (secondary outcome) over 2 years.A randomized, double-blind, placebo-controlled 20-week study with 2-year extension (sponsor unblinded at 20 weeks, participants/investigators at 1 year) in 19 European clinical research centers.A total of 564 adults (n=90-98 per group; body mass index 30-40 kg m(-2)) enrolled, 398 entered the extension and 268 completed the 2-year trial. Participants received diet (500 kcal deficit per day) and exercise counseling during 2-week run-in, before being randomly assigned (with a telephone or web-based system) to once-daily subcutaneous liraglutide (1.2, 1.8, 2.4 or 3.0 mg, n=90-95), placebo (n=98) or open-label orlistat (120 mg × 3, n=95). After 1 year, liraglutide/placebo recipients switched to liraglutide 2.4 mg, then 3.0 mg (based on 20-week and 1-year results, respectively). The trial ran from January 2007-April 2009 and is registered with Clinicaltrials.gov, number NCT00480909.From randomization to year 1, liraglutide 3.0 mg recipients lost 5.8 kg (95% confidence interval 3.7-8.0) more weight than those on placebo and 3.8 kg (1.6-6.0) more than those on orlistat (P0.0001; intention-to-treat, last-observation-carried-forward). At year 2, participants on liraglutide 2.4/3.0 mg for the full 2 years (pooled group, n=184) lost 3.0 kg (1.3-4.7) more weight than those on orlistat (n=95; P<0.001). Completers on liraglutide 2.4/3.0 mg (n=92) maintained a 2-year weight loss of 7.8 kg from screening. With liraglutide 3.0 mg, 20-week body fat decreased by 15.4% and lean tissue by 2.0%. The most frequent drug-related side effects were mild to moderate, transient nausea and vomiting. With liraglutide 2.4/3.0 mg, the 2-year prevalence of prediabetes and metabolic syndrome decreased by 52 and 59%, with improvements in blood pressure and lipids.Liraglutide is well tolerated, sustains weight loss over 2 years and improves cardiovascular risk factors." @default.
• W1994320162 created "2016-06-24" @default.
• W1994320162 creator A5017239784 @default.
• W1994320162 creator A5018535962 @default.
• W1994320162 creator A5020700497 @default.
• W1994320162 creator A5025549582 @default.
• W1994320162 creator A5035293496 @default.
• W1994320162 creator A5037824940 @default.
• W1994320162 creator A5044474855 @default.
• W1994320162 creator A5048168425 @default.
• W1994320162 creator A5050568080 @default.
• W1994320162 creator A5056587381 @default.
• W1994320162 creator A5059778565 @default.
• W1994320162 creator A5082931469 @default.
• W1994320162 date "2011-08-16" @default.
• W1994320162 modified "2023-10-09" @default.
• W1994320162 title "Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide" @default.
• W1994320162 cites W1964607854 @default.
• W1994320162 cites W1991988767 @default.
• W1994320162 cites W1993747099 @default.
• W1994320162 cites W2004409542 @default.
• W1994320162 cites W2005230361 @default.
• W1994320162 cites W2012757283 @default.
• W1994320162 cites W2030142553 @default.
• W1994320162 cites W2034735484 @default.
• W1994320162 cites W2053986195 @default.
• W1994320162 cites W2083531457 @default.
• W1994320162 cites W2098459806 @default.
• W1994320162 cites W2098590161 @default.
• W1994320162 cites W2101243738 @default.
• W1994320162 cites W2103525547 @default.
• W1994320162 cites W2110438413 @default.
• W1994320162 cites W2110447016 @default.
• W1994320162 cites W2113419157 @default.
• W1994320162 cites W2119779723 @default.
• W1994320162 cites W2123289485 @default.
• W1994320162 cites W2136335834 @default.
• W1994320162 cites W2152835319 @default.
• W1994320162 cites W2158822657 @default.
• W1994320162 cites W2334902808 @default.
• W1994320162 cites W2726799618 @default.
• W1994320162 cites W4230870013 @default.
• W1994320162 doi "https://doi.org/10.1038/ijo.2011.158" @default.
• W1994320162 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3461573" @default.
• W1994320162 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21844879" @default.
• W1994320162 hasPublicationYear "2011" @default.
• W1994320162 type Work @default.
• W1994320162 sameAs 1994320162 @default.
• W1994320162 citedByCount "514" @default.
• W1994320162 countsByYear W19943201622012 @default.
• W1994320162 countsByYear W19943201622013 @default.
• W1994320162 countsByYear W19943201622014 @default.
• W1994320162 countsByYear W19943201622015 @default.
• W1994320162 countsByYear W19943201622016 @default.
• W1994320162 countsByYear W19943201622017 @default.
• W1994320162 countsByYear W19943201622018 @default.
• W1994320162 countsByYear W19943201622019 @default.
• W1994320162 countsByYear W19943201622020 @default.
• W1994320162 countsByYear W19943201622021 @default.
• W1994320162 countsByYear W19943201622022 @default.
• W1994320162 countsByYear W19943201622023 @default.
• W1994320162 crossrefType "journal-article" @default.
• W1994320162 hasAuthorship W1994320162A5017239784 @default.
• W1994320162 hasAuthorship W1994320162A5018535962 @default.
• W1994320162 hasAuthorship W1994320162A5020700497 @default.
• W1994320162 hasAuthorship W1994320162A5025549582 @default.
• W1994320162 hasAuthorship W1994320162A5035293496 @default.
• W1994320162 hasAuthorship W1994320162A5037824940 @default.
• W1994320162 hasAuthorship W1994320162A5044474855 @default.
• W1994320162 hasAuthorship W1994320162A5048168425 @default.
• W1994320162 hasAuthorship W1994320162A5050568080 @default.
• W1994320162 hasAuthorship W1994320162A5056587381 @default.
• W1994320162 hasAuthorship W1994320162A5059778565 @default.
• W1994320162 hasAuthorship W1994320162A5082931469 @default.
• W1994320162 hasBestOaLocation W19943201621 @default.
• W1994320162 hasConcept C126322002 @default.
• W1994320162 hasConcept C134018914 @default.
• W1994320162 hasConcept C141071460 @default.
• W1994320162 hasConcept C142724271 @default.
• W1994320162 hasConcept C168563851 @default.
• W1994320162 hasConcept C197934379 @default.
• W1994320162 hasConcept C204243189 @default.
• W1994320162 hasConcept C204787440 @default.
• W1994320162 hasConcept C27081682 @default.
• W1994320162 hasConcept C2777180221 @default.
• W1994320162 hasConcept C2778375690 @default.
• W1994320162 hasConcept C2780221984 @default.
• W1994320162 hasConcept C2780780548 @default.
• W1994320162 hasConcept C2781308992 @default.
• W1994320162 hasConcept C511355011 @default.
• W1994320162 hasConcept C544821477 @default.
• W1994320162 hasConcept C555293320 @default.
• W1994320162 hasConcept C71924100 @default.
• W1994320162 hasConceptScore W1994320162C126322002 @default.
• W1994320162 hasConceptScore W1994320162C134018914 @default.
• W1994320162 hasConceptScore W1994320162C141071460 @default.
• W1994320162 hasConceptScore W1994320162C142724271 @default.
• W1994320162 hasConceptScore W1994320162C168563851 @default.

• next